Sun Pharmaceutical Industries Limited announced that USFDA has granted its subsidiary an approval for an Abbreviated New Drug Application (ANDA) for generic Casodex bicalutamide tablets.

These bicalutamide tablets, USP 50 mg are therapeutically equivalent to Cadodex tablets from AstraZeneca.

Reports suggest that, Casodex tablets have annual sales of approximately USD 314 million in the US.

Bicalutamide tablets are an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of stage D2 metastatic carcinoma of the prostate.

The scrip of sun pharmaceutical closed today at Rs 1142, marginal down compared to its previous close.